Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 25

1.

Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression.

Hebb JPO, Mosley AR, Vences-Catalán F, Rajasekaran N, Rosén A, Ellmark P, Felsher DW.

Cancer Immunol Immunother. 2018 Jan;67(1):47-60. doi: 10.1007/s00262-017-2059-y. Epub 2017 Sep 13.

PMID:
28905118
2.

Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer.

van Hooren L, Sandin LC, Moskalev I, Ellmark P, Dimberg A, Black P, Tötterman TH, Mangsbo SM.

Eur J Immunol. 2017 Feb;47(2):385-393. doi: 10.1002/eji.201646583. Epub 2016 Dec 13.

3.

Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation.

Ellmark P, Mangsbo SM, Furebring C, Norlén P, Tötterman TH.

Cancer Immunol Immunother. 2017 Jan;66(1):1-7. doi: 10.1007/s00262-016-1909-3. Epub 2016 Oct 6. Review.

4.

Kick-starting the cancer-immunity cycle by targeting CD40.

Ellmark P, Mangsbo SM, Furebring C, Tötterman TH, Norlén P.

Oncoimmunology. 2015 Mar 16;4(7):e1011484. eCollection 2015 Jul.

5.

The human agonistic CD40 antibody ADC-1013 eradicates bladder tumors and generates T-cell-dependent tumor immunity.

Mangsbo SM, Broos S, Fletcher E, Veitonmäki N, Furebring C, Dahlén E, Norlén P, Lindstedt M, Tötterman TH, Ellmark P.

Clin Cancer Res. 2015 Mar 1;21(5):1115-26. doi: 10.1158/1078-0432.CCR-14-0913. Epub 2014 Oct 14.

6.

Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer.

Sandin LC, Orlova A, Gustafsson E, Ellmark P, Tolmachev V, Tötterman TH, Mangsbo SM.

Cancer Immunol Res. 2014 Jan;2(1):80-90. doi: 10.1158/2326-6066.CIR-13-0067. Epub 2013 Oct 21.

7.

Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo.

Sandin LC, Eriksson F, Ellmark P, Loskog AS, Tötterman TH, Mangsbo SM.

Oncoimmunology. 2014 Jan 1;3(1):e27614. Epub 2014 Jan 16.

8.

Synergistic augmentation of CD40-mediated activation of antigen-presenting cells by amphiphilic poly(γ-glutamic acid) nanoparticles.

Broos S, Sandin LC, Apel J, Tötterman TH, Akagi T, Akashi M, Borrebaeck CA, Ellmark P, Lindstedt M.

Biomaterials. 2012 Sep;33(26):6230-9. doi: 10.1016/j.biomaterials.2012.05.011. Epub 2012 Jun 9.

PMID:
22687756
9.

Attovial-based antibody nanoarrays.

Ellmark P, Ghatnekar-Nilsson S, Meister A, Heinzelmann H, Montelius L, Wingren C, Borrebaeck CA.

Proteomics. 2009 Dec;9(24):5406-13. doi: 10.1002/pmic.200800962.

PMID:
19798667
10.

Multiplexed lipid dip-pen nanolithography on subcellular scales for the templating of functional proteins and cell culture.

Sekula S, Fuchs J, Weg-Remers S, Nagel P, Schuppler S, Fragala J, Theilacker N, Franzreb M, Wingren C, Ellmark P, Borrebaeck CA, Mirkin CA, Fuchs H, Lenhert S.

Small. 2008 Oct;4(10):1785-93. doi: 10.1002/smll.200800949.

PMID:
18814174
11.

Detection of pancreatic cancer using antibody microarray-based serum protein profiling.

Ingvarsson J, Wingren C, Carlsson A, Ellmark P, Wahren B, Engström G, Harmenberg U, Krogh M, Peterson C, Borrebaeck CA.

Proteomics. 2008 Jun;8(11):2211-9. doi: 10.1002/pmic.200701167.

PMID:
18528842
12.

Sensitivity of HIV type 1 primary isolates to human anti-CD40 antibody-mediated suppression is related to coreceptor use.

Abayneh SA, Ellmark P, Karlsson U, Andersson H, Borrebaeck CA, Karlsson I, Fenyö EM.

AIDS Res Hum Retroviruses. 2008 Mar;24(3):447-52. doi: 10.1089/aid.2007.0216.

PMID:
18373433
13.

The applicability of a cluster of differentiation monoclonal antibody microarray to the diagnosis of human disease.

Ellmark P, Woolfson A, Belov L, Christopherson RI.

Methods Mol Biol. 2008;439:199-209. doi: 10.1007/978-1-59745-188-8_14.

PMID:
18370105
14.

Phenotypic protein profiling of different B cell sub-populations using antibody CD-microarrays.

Ellmark P, Högerkorp CM, Ek S, Belov L, Berglund M, Rosenquist R, Christopherson RI, Borrebaeck CA.

Cancer Lett. 2008 Jun 28;265(1):98-106. doi: 10.1016/j.canlet.2008.02.006. Epub 2008 Mar 18.

PMID:
18353541
15.

Identification of a strongly activating human anti-CD40 antibody that suppresses HIV type 1 infection.

Ellmark P, Andersson H, Abayneh S, Fenyö EM, Borrebaeck CA.

AIDS Res Hum Retroviruses. 2008 Mar;24(3):367-73. doi: 10.1089/aid.2007.0215.

PMID:
18327984
16.

Serum proteome profiling of metastatic breast cancer using recombinant antibody microarrays.

Carlsson A, Wingren C, Ingvarsson J, Ellmark P, Baldertorp B, Fernö M, Olsson H, Borrebaeck CA.

Eur J Cancer. 2008 Feb;44(3):472-80. doi: 10.1016/j.ejca.2007.11.025. Epub 2008 Jan 2.

PMID:
18171612
17.

The application of CD antigen proteomics to pharmacogenomics.

Woolfson A, Ellmark P, Chrisp JS, A Scott M, Christopherson RI.

Pharmacogenomics. 2006 Jul;7(5):759-71. Review.

PMID:
16886900
18.

Identification of protein expression signatures associated with Helicobacter pylori infection and gastric adenocarcinoma using recombinant antibody microarrays.

Ellmark P, Ingvarsson J, Carlsson A, Lundin BS, Wingren C, Borrebaeck CA.

Mol Cell Proteomics. 2006 Sep;5(9):1638-46. Epub 2006 Jul 13.

19.

Multiplex detection of surface molecules on colorectal cancers.

Ellmark P, Belov L, Huang P, Lee CS, Solomon MJ, Morgan DK, Christopherson RI.

Proteomics. 2006 Mar;6(6):1791-802.

PMID:
16485257
20.

A novel mammalian display system for the selection of protein-protein interactions by decoy receptor engagement.

Ellmark P, Ohlin M, Borrebaeck CA, Furebring C.

J Mol Recognit. 2004 Jul-Aug;17(4):316-22.

PMID:
15227638

Supplemental Content

Loading ...
Support Center